A novel two-step administration of XPO-1 inhibitor may enhance the effect of anti-BCMA CAR-T in relapsed/refractory extramedullary multiple myeloma

BACKGROUND: Extramedullary disease usually implies a dismal outcome in relapsed/refractory multiple myeloma patients, and requires novel treatment approaches. We designed a trial using Selinexor, a nuclear export protein 1 inhibitor, together with anti-B cell maturation antigen (BCMA) chimeric antig...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Di, Fu, Haiying, Que, Yimei, Ruan, Haitao, Xu, Menglei, Long, Xiaolu, Yu, Qiuxia, Li, Chunhui, Li, Zhe, Cai, Songbai, Chen, Wei, Sun, Cong, Hu, Guang, Wang, Shuai, He, Donggou, Mei, Jianming, Wang, Wen, Li, Chunrui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647128/
https://www.ncbi.nlm.nih.gov/pubmed/37964302
http://dx.doi.org/10.1186/s12967-023-04655-w

Ejemplares similares

Ejemplares similares